

71

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on August 28, 2003

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

1651
\$


INFORMATION DISCLOSURE
STATEMENT

Examining Group 1651

Patent Application

Docket No. USF-T173CXC1

Serial No. 09/914,508



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Vera Afremova
Art Unit : 1651
Applicant : Beerelli Seshi
Serial No. : 09/914,508
Filed : November 7, 2001
Confirm. No. : 8090
For : Human Mesenchymal Progenitor Cell

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.


09/04/2003 NROCHA1 00000022 190065 09914508

01 FC:1806

180.00 DA

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein.



Please place a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2			Complete if Known	
			Application Number	09/914,508
			Filing Date	November 7, 2001
			First Named Inventor	Beerelli Seshi
			Group Art Unit	1651
			Examiner Name	Vera Afremova
			Attorney Docket Number	USF-T173CXC1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	10/263,419		Seshi (patent application)	10-03-2002	All
	U2	5,942,225		Bruder et al.	08-24-1999	All
	U3	6,010,696		Caplan et al.	01-04-2000	All
	U4	5,733,542		Haynesworth et al.	03-31-1998	All
	U5	5,486,359		Caplan et al.	01-23-1996	All
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					
	U15					
	U16					
	U17					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/914,508
				Filing Date	November 7, 2001
				First Named Inventor	Beerelli Seshi
				Group Art Unit	1651
				Examiner Name	Vera Afremova
Sheet	2	of	2	Attorney Docket Number	USF-T173CXC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R1	DEXTER, T.M. <i>et al.</i> "conditions Controlling the Proliferation of Haemopoietic Stem Cells In Vitro" <i>J. Cell. Physiol.</i> , 1977, 91(3):335-344.		
	R2	GREENBERGER, J.S. "Sensitivity of corticosteroid-dependent insulin-resistant lipogenesis in marrow preadipocytes of obese-diabetic (db/db) mice" <i>Nature</i> , October 26, 1978, 275:752-754.		
	R3	SESHI, B. <i>et al.</i> "Human Bone Marrow Stromal Cell: Coexpression of Markers Specific for Multiple Mesenchymal Cell Lineages" <i>Blood Cells, Molecules, and Diseases</i> , June 2000, 26(3):234-246.		
	R4	SESHI, B. "Discovery of Novel Hematopoietic Cell Adhesion Molecules From Human Bone Marrow Stromal Cell Membrane Protein Extracts by a New Cell-Blotting Technique" <i>Blood</i> , May 1994, 83(9):2399-2409.		
	R5	BORDIGNON, C. <i>et al.</i> "Cell Therapy: Achievements and Perspectives" <i>Haematologica</i> , 1999, 84:1110-1149.		
	R6	GARTNER, S. and H.S. KAPLAN "Long-term culture of human bone marrow cells" <i>Proc. Natl. Acad. Sci. USA</i> , August 1980, 77(8):4756-4759.		
	R7	DEXTER, T.M. <i>et al.</i> "Long-Term Marrow Culture: An Overview of Techniques and Experience" in Long-Term Bone Marrow Culture, Wright, D.G. <i>et al.</i> , Eds., 1984, pp. 57-96.		
	R8	MARINI, F. <i>et al.</i> "Mesenchymal Stem Cells (MSC) from Patients with Chronic Myelogenous Leukemia (CML) Patients can be Transduced with Common Gene Transfer Vectors at High Efficiency, and are Genotypically Normal" Abstract from American Society of Hematology 42 nd Annual Meeting, Part 1. December 1-5, 2000. San Francisco, Ca.		
	R9	KEATING, A. <i>et al.</i> "Effect of Different Promoters on Expression of Genes Introduced into Hematopoietic and Marrow Stromal Cells by Electroporation" <i>Exp. Hematol.</i> , 1990, 18:99-102.		
	R10			
	R11			
	R12			
	R13			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.